XML 14 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues $ 41,927 $ 31,916
Cost of products sold 30,457 24,480
Gross profit 11,470 7,436
Operating expenses:    
Research and development 1,756 2,032
Selling, general and administrative 5,651 5,378
Total operating expenses 7,407 7,410
Operating income 4,063 26
Interest and financing expense (520) (424)
Miscellaneous income (expense) 64 (70)
Total other expense (456) (494)
Income (loss) before income taxes 3,607 (468)
Income tax provision (benefit) 703 (133)
Net income (loss) 2,904 (335)
Net income attributable to non-controlling interest 13 11
Net income (loss) attributable to Ultralife Corporation 2,891 (346)
Other comprehensive loss:    
Foreign currency translation adjustments (232) 197
Comprehensive income attributable to Ultralife Corporation $ 2,659 $ (149)
Net income (loss) per share attributable to Ultralife common stockholders – basic (in dollars per share) $ 0.21 $ 0.03
Net income (loss) per share attributable to Ultralife common stockholders – diluted (in dollars per share) $ 0.21 $ 0.03
Weighted average shares outstanding – basic (in shares) 16,396 16,135
Potential common shares (in shares) 122 0
Weighted average shares outstanding - diluted (in shares) 16,518 16,135